Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the european organization for research and treatment of cancer investigational drug branch for breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 9, 1997, Pages 3149-3155

  Piccart, M J ^a   Klijn, J ^a   Paridaens, R ^a   Nooij, M ^a   Mauriac, L ^a   Coleman, R ^a   Bontenbal, M ^a   Awada, A ^a   Selleslags, J ^a   Van Vreckem, A ^a   Van Glabbeke, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DOCETAXEL; METHYLPREDNISOLONE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DRUG APPROVAL; DRUG EFFICACY; FEMALE; FLUID RETENTION; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0030765203     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.9.3149     Document Type: Article

References (17)

1. Piccart M: Taxoid compounds in breast cancer: Current status and future prospects, in Muggia FM (ed): Concepts, Mechanisms, and New Targets for Chemotherapy. Boston, MA, Kluwer, 1995, pp 185-207
2. Piccart M: Taxol and Taxotere: New drugs of interest in the treatment of advanced ovarian cancer, in Sharp F, Mason P, Blackett T, et al (eds): Ovarian Cancer 3. London, United Kingdom, Chapman & Hall, 1993, pp 215-223
3. Piccart MJ, Raymond E, Aapro M, et al: Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: Current status and future prospects. Eur J Cancer 31A:S1-S10, 1995 (suppl 7)
4. Kaye B, Piccart MJ, Aapro M, et al: Docetaxel in advanced ovarian cancer: Preliminary results from 3 phase II trials. Eur J Cancer 31A:S14-S17, 1995 (suppl 4)
5. Piccart MJ, Gore M, Ten Bokkel Huinink W, et al: Docetaxel: An active new drug for the treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87 :676-681, 1995
6. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
7. Bissery M-C, Vrignaud P, Lavelle F: Preclinical profile of docetaxel (Taxotere): Efficacy as a single agent and in combination. Semin Oncol 22:3-16, 1995 (suppl 13)
8. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of docetaxel administered as 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458-1467, 1994
9. Tomiak E, Kerger J, Lips S, et al: Unexpected pleural changes observed in patients treated with Taxotere (RP 56976): A new drug toxicity? Ann Oncol 3:48, 1992 (suppl 5; abstr 189)
10. Schrijvers D, Wanders J, Dirix L, et al: Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4:610-611, 1993
11. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428, 1996
12. Hudis CA, Seidman AD, Crown JPA, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
13. Piccart MJ: Docetaxel: A new defence in the management of breast cancer. Anticancer Drugs 6:7-11, 1995 (suppl 4)
14. Ravdin PM, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
15. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
16. Oulid-Aissa D, Béhir A, Spielmann M, et al: Management of fluid retention syndrome in patients treated with Taxotere (docetaxel): Effect of premedication. Proc Am Soc Clin Oncol 13:465, 1994 (abstr 1614)
17. Rhône-Poulenc Rorer: Data on file. International Registration Department, Antony, France, 1994